Gynecological carcinosarcomas: Overview and future perspectives.

Area of Science:

• Gynecologic Oncology
• Cancer Genomics
• Tumor Pathology

Background:

• Gynecologic carcinosarcomas (CS) are rare, aggressive neoplasms comprising both high-grade carcinoma and sarcoma components.
• They represent less than 5% of uterine and ovarian malignancies, characterized by a poor prognosis with a 5-year overall survival rate below 30%.

Purpose of the Study:

• To provide a comprehensive review of uterine (UCS) and ovarian (OCS) carcinosarcomas.
• To discuss epidemiology, pathology, genomic landscape, current therapeutic strategies, and future perspectives for these rare tumors.

Main Methods:

• Extensive literature review on gynecologic carcinosarcomas.
• Analysis of epidemiological data, pathological features, and genomic profiles.
• Evaluation of current treatment modalities and emerging therapeutic strategies.

Main Results:

• CS are aggressive with poor outcomes, especially in advanced stages where chemotherapy offers limited response rates.
• Current treatment involves surgery and adjuvant therapy, but limited clinical trial inclusion hinders therapeutic advancement.
• Recent molecular discoveries offer potential for novel therapeutic approaches.

Conclusions:

• Gynecologic carcinosarcomas require further research due to their aggressive nature and poor prognosis.
• Understanding the genomic landscape is crucial for developing targeted therapies.
• Future research and clinical trial inclusion are essential to improve outcomes for CS patients.